Moreover, Fisher et al. [25] showed that the combination of adoptively transferred Vδ2+ T-cells, expanded in vitro with ZOL and IL-2, with dinutuximab and systemic ZOL suppressed tumour growth compared to antibody or γδT cell-free controls in an immunodeficient mouse model of small established GD2-expressing NB tumours. This evidence concerns the gene IL2 and neoplasm.